Related Experiment Video

Updated: Jul 19, 2026

Modifying Levels of Maternal Dietary Folic Acid or Choline to Study the Impact of Deficiencies on Offspring Health Outcomes
03:19

Modifying Levels of Maternal Dietary Folic Acid or Choline to Study the Impact of Deficiencies on Offspring Health Outcomes

Published on: June 28, 2024

Safety and efficacy of early amino acids in preterm <28 weeks gestation: prospective observational comparison

K Kotsopoulos1, A Benadiba-Torch, A Cuddy

  • 1Department of Paediatrics, Mount Sinai Hospital, University of Toronto, Toronto, Canada.

Journal of Perinatology : Official Journal of the California Perinatal Association
|October 7, 2006
PubMed

Insights

Early administration of amino acids (AA) to preterm neonates is safe and may reduce sepsis incidence. This nutritional strategy also helps infants regain birth weight faster.

Area of Science:

  • Neonatal Medicine
  • Pediatric Nutrition
  • Clinical Research

Background:

  • Preterm neonates (<28 weeks gestational age) have unique nutritional needs.
  • Timely initiation of nutrition is critical for growth and development in extremely premature infants.

Purpose of the Study:

  • To evaluate the safety and efficacy of early amino acid (AA) administration in preterm neonates.
  • To compare outcomes between early and late AA initiation in this vulnerable population.

Main Methods:

  • Prospective data collection over two years, comparing a late AA group (12-30h) with an early AA group (immediately after stabilization).
  • Assessment of metabolic acidosis, blood urea levels, growth rates, and neonatal outcomes.

Main Results:

  • Early AA initiation occurred significantly sooner (4+/-3h vs 20+/-6h).
  • No significant differences in metabolic acidosis or overall growth were observed.
  • The early AA group showed reduced incidence of sepsis and faster time to regain birth weight.

Conclusions:

  • Early amino acid administration in preterm neonates is safe and not associated with adverse effects.
  • Early AA supplementation is linked to a reduction in sepsis and improved time to regain birth weight.
Abstract

More Related Videos

The 4-vessel Sampling Approach to Integrative Studies of Human Placental Physiology In Vivo12:17

The 4-vessel Sampling Approach to Integrative Studies of Human Placental Physiology In Vivo

Published on: August 2, 2017

Modeling Encephalopathy of Prematurity Using Prenatal Hypoxia-ischemia with Intra-amniotic Lipopolysaccharide in Rats07:36

Modeling Encephalopathy of Prematurity Using Prenatal Hypoxia-ischemia with Intra-amniotic Lipopolysaccharide in Rats

Published on: November 20, 2015

Related Concept Videos

Teratogenicity01:07

Teratogenicity

The ability of a drug to produce structural deformations and functional abnormalities in the developing embryo or the fetus is called teratogenicity, and the drug producing this effect is known as a teratogen. Teratogenic effects include stillbirth, miscarriage, intrauterine growth restriction, and neurocognitive delay. A teratogen may affect the embryo at different stages of development, which is important in determining the type and extent of the damage. During blastocyst formation, the early...
Bioavailability Study Design: Healthy Subjects Versus Patients01:15

Bioavailability Study Design: Healthy Subjects Versus Patients

Bioavailability studies are essential for evaluating a drug's therapeutic efficacy and understanding its absorption patterns under various physiological conditions. Conducting such studies on target patient populations provides more relevant data by simulating real-world disease states. However, practical challenges often necessitate the use of young, healthy adult volunteers as study subjects.Patients may exhibit altered drug absorption patterns due to the effects of the disease itself,...
Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
Bioavailability Study Design: Absolute Versus Relative Bioavailability01:27

Bioavailability Study Design: Absolute Versus Relative Bioavailability

Bioavailability is a crucial pharmacokinetic parameter that quantifies the proportion of an administered drug that reaches the systemic circulation and is available for therapeutic action. Regulatory agencies mandate the assessment of bioavailability, typically measured as the area under the drug plasma concentration-versus-time curve (AUC), to ensure the efficacy and safety of pharmaceutical products. These evaluations are categorized as absolute and relative bioavailability studies.Absolute...
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...